Neurodegeneration News and Research

RSS

Neurodegeneration is the umbrella term for the progressive loss of structure or function of neurons, including death of neurons.

Study reveals hidden internal structure within biomolecular condensates

Cells rely on biomolecular condensates to coordinate essential biological processes without surrounding membranes.

25 Feb 2026

SwRI advances safer manufacturing of nerve agent antidotes

Southwest Research Institute (SwRI) continues to expand its unique drug synthesis capabilities and expertise to advance the scalable manufacturing of safer antidotes to combat exposure to organophosphorus nerve agents (OPNAs) and pesticides.

24 Feb 2026

New review explores whether berries can slow cognitive decline linked to obesity

This systematic review in Nutrients evaluates human studies investigating whether polyphenol-rich berry consumption can modulate obesity-related metabolic dysfunction and support cognitive performance, particularly in individuals at risk of mild cognitive impairment. Evidence suggests modest memory benefits and possible metabolic improvements, although biomarker findings and long-term clinical relevance remain uncertain.

22 Feb 2026

Single blood test predicts onset of Alzheimer’s symptoms years ahead

Researchers at Washington University School of Medicine in St. Louis have developed a method to predict when someone is likely to develop symptoms of Alzheimer's disease using a single blood test.

19 Feb 2026

IFN-γ identified as a powerful blood biomarker for Alzheimer’s

This study identifies IFN-γ as a crucial blood-based biomarker for Alzheimer's, revealing its role in microglial inflammation and genetic risk interactions.

19 Feb 2026

Can GLP-1 drugs slow neurodegeneration? New review finds promising signals but limited clinical proof

This review examines how GLP-1 receptor agonists may influence neurodegenerative disease biology through metabolic, inflammatory, mitochondrial, and proteostasis pathways. Evidence from mechanistic, preclinical, and early clinical studies suggests potential neuroprotective effects, but definitive disease-modifying benefit remains unproven.

17 Feb 2026

Scientists uncover nanoplastics in brain tissue and question their role in neurological disease

Emerging evidence suggests nanoplastics accumulate in human tissues including the brain and may contribute to neuroinflammation and neurodegenerative disease pathways. However, causality, exposure routes, and long-term health effects remain uncertain and require coordinated research.

17 Feb 2026

JAX-NYSCF collaborates with GSK to advance human cellular models of neurodegenerative disease

The Jackson Laboratory–New York Stem Cell Foundation Collaborative (JAX-NYSCF) today announced a five-year strategic research collaboration with GSK focused on advancing human cellular models of neurodegenerative disease, including Alzheimer's disease.

17 Feb 2026

Senescent astrocytes identified as key drivers of Alzheimer's progression

Researchers from the NeuroAD group (Neuropathology of Alzheimer's Disease) within the Department of Cell Biology, Genetics and Physiology at the University of Málaga, also affiliated with IBIMA-BIONAND Platform and CIBERNED, have made a pioneering breakthrough in the fight against this disease by identifying astrocytes as a promising cellular target for the development of future therapies.

16 Feb 2026

Neuron lattice structure may guard against neurodegeneration

Brain cells are constantly swallowing material from the fluid that surrounds them - signaling molecules, nutrients, even pieces of their own surfaces - in a process known as endocytosis that is essential for learning, memory and basic neural upkeep.

11 Feb 2026

New roadmap integrates aging into Parkinson disease models

Even though aging is the largest risk factor for Parkinson's disease, the majority of research aimed at taming the able neurodegenerativeincur motor disease has largely left aging out of the mix.

11 Feb 2026

Alzheimer’s plaques decline after CAR-T immune cell treatment in preclinical study

Researchers engineered CD4+ chimeric antigen receptor T cells targeting fibrillar amyloid beta and tested them in a mouse Alzheimer model. The preclinical study showed reduced amyloid pathology and altered neuroimmune responses, supporting CAR-T immunotherapy as a potential future Alzheimer strategy.

11 Feb 2026